Inhibitex to Present Data from Its HCV Development Program at the 44th Annual Meeting of the European Association for the Stu...
April 15 2009 - 11:45AM
Business Wire
Inhibitex, Inc. (NASDAQ: INHX) announced today that a poster
presentation detailing preclinical data from its HCV nucleoside
polymerase inhibitor program will be presented by Dr. John
Vernachio, vice president of biology, at the 44th Annual Meeting of
the European Association for the Study of the Liver (EASL) in
Copenhagen, Denmark on Saturday, April 25th. The full abstract can
be viewed at the EASL website at www.easl.ch.
The accepted abstract is as follows:
CHARACTERIZATION OF A SERIES OF HIGHLY POTENT PHOSPHORAMIDATE
NUCLEOSIDE ANALOGUE INHIBITORS OF HEPATITIS C POLYMERASE -
Poster # 969; Poster Presentation; Saturday, April 25. 2009;
Session time: 8:00-18:00.
About HCV
Hepatitis C is a disease of the liver caused by the hepatitis C
virus (HCV). It is estimated that approximately 4 million Americans
and 170 million individuals worldwide are infected with HCV. HCV
can cause chronic liver disease, cirrhosis and cancer, and is the
leading cause of liver transplant in the United States. Inhibitex
is developing a series of phosphoramidate nucleoside analogues, or
protides, which target the RNA-dependent RNA polymerase (NS5b) of
HCV. The Company believes that its protides possess several
pharmacological advantages over nucleosides alone, which include a
significant increase in antiviral activity, higher concentrations
of the triphosphate in liver, and potentially less toxicity due to
reduced systemic exposure.
About Inhibitex
Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a
biopharmaceutical company focused on developing products to treat
and prevent serious infectious diseases. The Company�s pipeline
includes FV-100, its clinical-stage oral nucleoside analogue in
development for the treatment of herpes zoster (shingles), as well
as a series of HCV nucleoside polymerase inhibitors and HIV
integrase inhibitors. Inhibitex has also licensed certain of its
proprietary MSCRAMM� protein technology to Wyeth for the
development of staphylococcal vaccines.
For additional information about the Company, please visit
www.inhibitex.com.
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jul 2023 to Jul 2024
